Physician profile
Darryl Morin
NPI 1083892285
$5,037.83
in general payments reported to CMS, 2019-2025
29 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $950 · 2021: $1,255 · 2022: $130 · 2023: $293 · 2024: $710 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,263.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $442.14 | 2019-2022 | |
| Amarin Pharma, INC. | $390.83 | 2019-2021 | |
| Medtronic Vascular, INC. | $296.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $257.28 | 2019-2022 | |
| Pfizer INC. | $244.28 | 2019-2024 | |
| Gilead Sciences, INC. | $227.24 | 2019-2025 | Epclusa |
| Novo Nordisk INC | $219.70 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $218.87 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.95 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.32 | 2019-2021 | |
| Boston Scientific Corporation | $184.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $110.22 | 2023-2024 | Trelegy Ellipta |
| Abbvie INC. | $91.62 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.50 | 2021-2022 | |
| Exact Sciences Corporation | $74.65 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $71.04 | 2019 | |
| Abbott Laboratories | $41.59 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic, INC. | $36.18 | 2021 | |
| Seqirus USA INC | $34.52 | 2025 | Fluad, Flucelvax |
| Astellas Pharma US INC | $31.46 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $31.37 | 2019 | |
| Lilly USA, LLC | $26.69 | 2024 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.69 | 2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $17.94 | 2024 | Voquezna |
| Angiodynamics, INC. | $13.80 | 2021 | |
| Dexcom, INC. | $13.00 | 2023 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Morin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.